There is increasing evidence that PRAD–CSC–specific markers (CD44, CD133, CD166, FAM65 B, MFI2, and LEF1) can predict the patients' overall survival, which suggests the clinical potential of PRAD CSC as biomarkers and therapeutic targets [71, 72]. This evidence concerns the gene CD44 and prostate adenocarcinoma.